Logo image of PAE

PAE INC (PAE) Stock Fundamental Analysis

NASDAQ:PAE - Nasdaq - Common Stock

10.05  +0.01 (+0.1%)

After market: 10.05 0 (0%)

Fundamental Rating

1

PAE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 64 industry peers in the Aerospace & Defense industry. Both the profitability and financial health of PAE have multiple concerns. PAE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PAE had positive earnings in the past year.
PAE Yearly Net Income VS EBIT VS OCF VS FCFPAE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 0 20M 40M 60M 80M 100M

1.2 Ratios

Industry RankSector Rank
ROA 2.83%
ROE 45.14%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PAE Yearly ROA, ROE, ROICPAE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 0 2 4 6 8 10

1.3 Margins

Industry RankSector Rank
OM 3.48%
PM (TTM) 1.73%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PAE Yearly Profit, Operating, Gross MarginsPAE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 5 10 15 20

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, PAE has more shares outstanding
Compared to 1 year ago, PAE has a worse debt to assets ratio.
PAE Yearly Shares OutstandingPAE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 20M 40M 60M 80M
PAE Yearly Total Debt VS Total AssetsPAE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 500M 1B 1.5B

2.2 Solvency

PAE has an Altman-Z score of 2.24. This is not the best score and indicates that PAE is in the grey zone with still only limited risk for bankruptcy at the moment.
PAE has a Debt/Equity ratio of 7.59. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 7.59
Debt/FCF N/A
Altman-Z 2.24
ROIC/WACCN/A
WACCN/A
PAE Yearly LT Debt VS Equity VS FCFPAE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.25 indicates that PAE should not have too much problems paying its short term obligations.
PAE has a Quick Ratio of 1.25. This is a normal value and indicates that PAE is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.25
PAE Yearly Current Assets VS Current LiabilitesPAE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

PAE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.61%.
PAE shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.30%.
EPS 1Y (TTM)-21.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%181.82%
Revenue 1Y (TTM)54.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.5%

3.2 Future

Based on estimates for the next years, PAE will show a very strong growth in Earnings Per Share. The EPS will grow by 26.16% on average per year.
PAE is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.87% yearly.
EPS Next Y104.4%
EPS Next 2Y25.39%
EPS Next 3Y34.28%
EPS Next 5Y26.16%
Revenue Next Year12.63%
Revenue Next 2Y4.53%
Revenue Next 3Y6.24%
Revenue Next 5Y4.87%

3.3 Evolution

PAE Yearly Revenue VS EstimatesPAE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 1B 2B 3B
PAE Yearly EPS VS EstimatesPAE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

PAE is valuated rather expensively with a Price/Earnings ratio of 18.96.
Compared to an average S&P500 Price/Earnings ratio of 26.70, PAE is valued a bit cheaper.
PAE is valuated rather expensively with a Price/Forward Earnings ratio of 19.90.
PAE is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.49, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.96
Fwd PE 19.9
PAE Price Earnings VS Forward Price EarningsPAE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.25
PAE Per share dataPAE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

PAE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PAE's earnings are expected to grow with 34.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y25.39%
EPS Next 3Y34.28%

More info and screens

0

5. Dividend

5.1 Amount

PAE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAE INC

NASDAQ:PAE (2/14/2022, 4:12:28 PM)

After market: 10.05 0 (0%)

10.05

+0.01 (+0.1%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)11-04 2021-11-04
Earnings (Next)03-10 2022-03-10/bmo
Inst Owners0.81%
Inst Owner Change0%
Ins Owners0.69%
Ins Owner Change0%
Market Cap935.86M
Analysts75
Price Target11.86 (18.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 18.96
Fwd PE 19.9
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B 8.21
P/tB N/A
EV/EBITDA 10.25
EPS(TTM)0.53
EY5.27%
EPS(NY)0.51
Fwd EY5.02%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS31.93
BVpS1.22
TBVpSN/A
PEG (NY)0.18
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.83%
ROE 45.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 3.48%
PM (TTM) 1.73%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.63
Health
Industry RankSector Rank
Debt/Equity 7.59
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.25
Altman-Z 2.24
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%181.82%
EPS Next Y104.4%
EPS Next 2Y25.39%
EPS Next 3Y34.28%
EPS Next 5Y26.16%
Revenue 1Y (TTM)54.3%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.5%
Revenue Next Year12.63%
Revenue Next 2Y4.53%
Revenue Next 3Y6.24%
Revenue Next 5Y4.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A